A recent study indicates that people who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who halt traditional lifestyle regimens.
Published data in a leading medical journal shows that while obese individuals can lose substantial amounts of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying these medications must be aware of the risk of rapid rebound weight gain when the treatment is stopped," warns expert Dr. Susan Jebb.
That rate of recovery means a reversion to starting weight in about a year and a half.
Weighing Treatments
The analysis, which examined dozens of studies involving over 9,000 of patients, contrasted the results of GLP-1 agonists with conventional dieting.
Researchers emphasize that individuals who shed pounds through diet and exercise typically see a slower creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Rapid Rebound
Doctors propose the mode of action of the injections accounts for the accelerated regain.
These medications mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement results in hunger is no longer kept in check, making binge eating much more probable."
An Ongoing Issue?
The NHS advise the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Many experts argue that, given the high risk of weight regain, the therapy is often life-long.
This opinion is reinforced by drug manufacturers, who state that the findings "highlight the long-term nature of obesity," akin to managing conditions like diabetes.
User Testimonies
People who have stopped the medication describe a powerful return of appetite.
"It was like a trigger activating and you're instantly starving," recalled an individual.
This difficulty is compounded if users have not established sustainable lifestyle or habit modifications during therapy.
Significant Use
Survey data indicate that millions of adults in the UK have used these injections in the past year, with desire continuing to grow.
- Adoption is higher among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians stress that while these medications are potent agents for shedding pounds, they are not a standalone solution and maintained weight loss hinges on ongoing behavioural changes.
